Intercytex begins phase 2 diabetic foot ulcers trial of ICX-PRO

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Intercytex Group plc has started a phase 2 trial of ICX-PRO for the treatment of diabetic foot ulcers, according to a company news release.

ICX-PRO is a topical wound-care product designed to stimulate active repair in persistent chronic wounds, including diabetic foot ulcers. It includes active, allogeneic, human dermal fibroblasts in a human fibrin-based gel.

This open-label trial is being conducted in up to 15 subjects with chronic diabetic foot ulcers that have failed to heal despite conventional treatment. Wound closure will be evaluated over a six-month period.

Cambridge, England-based Intercytex, a cell therapy company developing products for wound care and aesthetic medicine markets, is also recruiting for a phase 3 multicenter trial of ICX-PRO for the treatment of venous leg ulcers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.